Unia Europejska - fiński - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastiset aineet - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unia Europejska - fiński - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - influenssa, ihminen - influenssa, inaktivoitu, split virus tai pinta-antigeenia - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra tulee käyttää virallisten suositusten mukaisesti.

Unia Europejska - fiński - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karsinooma, ei-pienisoluinen keuhko - antineoplastiset aineet - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unia Europejska - fiński - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastiset aineet - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Unia Europejska - fiński - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - eturauhasen kasvaimet, kastraatio-resistentin - antineoplastiset aineet - treatment of adult patients with prostate cancer.

Unia Europejska - fiński - EMA (European Medicines Agency)

seqirus gmbh - influenssaviruksen pinta-antigeenit (hemagglutiniini ja neuraminidaasi), inaktivoitu seuraavista viruskannoista:a/california/7/2009 (h1n1)pdm09 - kaltainen kanta(a/brisbane/10/2010, wild type)a/switzerland/9715293/2013 (h3n2) - kaltainen kanta(a/south australia/55/2014, wild type)b/phuket/3073/2013–- kaltainen kanta(b/vaasa/9/2014, wild type) - influenza, human; immunization - rokotteet - influenssan profylaksia aikuisille, erityisesti niille, joilla on lisääntynyt riski liittyä komplikaatioihin. optaflu-rokotetta tulee käyttää virallisten ohjeiden mukaan.

Unia Europejska - fiński - EMA (European Medicines Agency)

elanco gmbh - grapiprant - muut tulehduskipu-ja reumalääkkeet, ei-steroidit - koirat - koirille lievän tai keskivaikean niveltulehduksen yhteydessä liittyvän kivun hoitoon.

Finlandia - fiński - Fimea (Suomen lääkevirasto)

avansor pharma oy - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi

Unia Europejska - fiński - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Finlandia - fiński - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - bicalutamide - tabletti, kalvopäällysteinen - 150 mg - bikalutamidi